Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Microtubule (MT)-targeting agents are successful chemotherapeutics due to their interference with MT dynamics, impacting mitosis, signaling, trafficking, and angiogenesis.
• These drugs are most effective against mitotic cells, but challenges include dose-limiting toxicities and drug resistance.

Purpose of the Study:

• To review current categories of MT-targeting agents.
• To discuss recent advancements in dual tubulin and kinase inhibitors.
• To highlight ongoing challenges and future directions for MT-targeting drugs.

Main Methods:

• Literature review of MT-targeting agents.
• Analysis of recent research on dual inhibitors.
• Discussion of clinical challenges and therapeutic strategies.

Main Results:

• MT-targeting agents are vital in cancer therapy, primarily by disrupting microtubule dynamics.
• Newer strategies focus on overcoming resistance and toxicity, with dual tubulin and kinase inhibitors emerging as a promising approach.
• Dual inhibitors offer potential for enhanced efficacy and reduced side effects compared to traditional MT agents.

Conclusions:

• Microtubule-targeting agents remain a cornerstone of cancer chemotherapy.
• Development of novel agents, particularly dual tubulin and kinase inhibitors, is crucial for improving treatment outcomes.
• Addressing drug resistance and toxicity is key to maximizing the clinical benefit of MT-targeting therapies.